Skip to main content

Table 1 Baseline characteristics of case and control groups

From: Cilostazol as an add-on therapy for patients with Alzheimer’s disease in Taiwan: a case control study

 

Case (N = 30)

Control (N = 30)

p-value

Age, years (mean ± SD)

82.8 ± 5.2

82.0 ± 5.9

0.580

Education, years (mean ± SD)

8.1 ± 4.3

7.6 ± 5.2

0.722

Gender, female (%)

21 (70.0)

25 (83.3)

0.222

1st MMSE

14.0 ± 6.5

14.9 ± 6.1

0.585

1st CDR_SB

8.8 ± 3.5

7.3 ± 3.1

0.103

2nd MMSE

11.5 ± 8.1

12.5 ± 7.3

0.617

2nd CDR_SB

9.9 ± 4.0

8.9 ± 3.4

0.290

ApoE ε4(+),n (%)

5 (16.7)

7 (23.3)

0.469

  1. Case: participants using cilostazol for one year; Control: participants matching case participants 1:1 for age and education but not using cilostazol for one year
  2. MMSE Mini-Mental Status Examination, CDR_SB Clinical Dementia Rating Sum of Boxes scale, ApoE apolipoprotein E